Treatment of bulimia with bupropion: a multicenter controlled trial.
In a placebo-controlled, double-blind study of the unique antidepressant agent bupropion in the treatment of nondepressed subjects with bulimia (bupropion group, N = 55; placebo group, N = 26), we found the drug significantly superior to placebo in reducing episodes of binge eating and purging. In general, side effects with bupropion were minimal. However, four subjects experienced grand mal seizures during treatment with bupropion, a frequency of seizures far higher than observed in previous studies with this drug. Pending a satisfactory explanation for the occurrence of these seizures, we recommend that bupropion not be administered alone to bulimic patients.
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D002032:Bulimia / Q000188:drug therapy*; D016642:Bupropion; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced; D005260:Female; D006801:Humans; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D010352:Patient Dropouts; D010919:Placebos; D011427:Propiophenones / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D011427:Propiophenones; D016642:Bupropion